SUPPLEMENTAL / BID BULLETIN

UNIVERSITY OF THE PHILIPPINES MANILA
The Health Sciences Center
Bids and Awards Committee 1
Taft Avenue, Manila
Trunk Line No. 8554-8400 Local 3014/3015

BID BULLETIN NO. 2023-79
17 November 2023

for the Supply and Delivery of Various Drugs and Medicines for Onco-Patients – CY 2024 (Framework Agreement)
BAC1-2023-10-0071

Pursuant to Section 22.5.1 of the 2016 Revised Implementing Rules and Regulations of Republic Act No. 9184, the Bids and Awards Committee 1 is issuing this bid bulletin to modify or amend the following items in the Bid Documents in response to and address the request / clarification of the prospective bidder/s who attended the pre-bid conference held on 10 November 2023:

1. *The following should be modified the **Unit Price / Total Amount** in the Bid Data Sheet, Schedule of Requirements, and in the Price Schedule (Annex) as:*

Item No.	Item Description	Qty	From	To	Total Amount
5	Carboplatin 10mg/mL, 15Ml, vial (IV)	1,500 pieces	8,300.00	***850.00***	***1,275,000.00***
53	Ondansetron 2mg/mL, 4mL ampule (IM, IV)	10,000 pieces	0.36	***360.00***	***3,600,000.00***

2. *The following should be modified the **Quantity / Total Amount** in the Bid Data Sheet, Schedule of Requirements, Technical Specifications, and in the Price Schedule (Annex) as:*

Item No.	Item Description	From	To	Unit Price	Total Amount
51	Morphine Sulfate 10 mg/mL, 1mL ampul (IM, IV, SC) or 16mg/mL, 1 mL ampul (IM, IV) (With PDEA Permit)	15 pieces	***17 pieces***	78.45	***1,333.65***
52	Omeprazole powder, 40 mg vial + 10 mL solvent ampul/vial (IV)	2,000 pieces	***2,174 pieces***	240.00	***521,760.00***
68	Trastuzumab 150 mg lyophilized powder (IV infusion) vial	900 pieces	***1,030 pieces***	26,025.24	***26,805,997.20***
69	Trastuzumab 600 mg/5 mL (120 mg/mL) solution for injection (SC), 5 mL vial	650 pieces	***730 pieces***	51,916.80	***37,899,264.00***
128	Sterile water for injection 50mL bottle/bag (no preservative)	1,800 pieces	***1,801 pieces***	50.00	***90,050.00***

3. *The following should be modified the **Specifications** in the Bid Data Sheet, Schedule of Requirements, Technical Specifications, and in the Price Schedule (Annex) as:*

Item No.	From	To
20	Docetaxel anhydrous 20 mg/0.5 mL, 0.5 mL vial (IV infusion)	Docetaxel anhydrous 20 mg/0.5 mL, 0.5 mL vial (IV infusion) ***or 20mg/ml, 1ml concentrate for solution for IV infusion (as trihydrate)***
21	Docetaxel anhydrous 40 mg/mL, 2 mL vial (IV infusion)	Docetaxel anhydrous 40 mg/mL, 2 mL vial (IV infusion) ***or 80 mg/4ml, 4ml concentrate for solution for IV infusion (as trihydrate)***

4. *Clarification:*

SPECIFICATIONS:

Item No.	Query	Remarks / Response
26	Epoetin alfa (recombinant human erythropoetin) 4000 IU/0.4 mL, pre-filled syringe (IV, SC) *The prospective bidder would like to clarify the legal basis of the hospital for its preference for the 0.4ml PFS.*	Under Rule II: Procurement Planning, Section 7.4 of the Revised IRR of RA 9184 dated 3 July 2023, the respective end-user or implementing units of the Procuring Entity shall be responsible for the changes to the PPMPs. The specifications listed is based on the requirements of the end-users and for new items to be bid, the end-user shall make a request to the Pharmacy before inclusion in the PPMP. Changes to the individual PPMPs and the consolidated APP may be undertaken every six (6) months or as often as may be required by the HOPE.
29	Filgrastim 300 micrograms/1.2 mL, vial (IV, SC) or 300 micrograms/mL, vial (IV, SC) *The prospective bidder would like to clarify if the hospital would consider 0.9m pre-filled syringe (PFS).*	
54	Oxaliplatin 50mg vial powder (IV Infusion) *The prospective bidder would like to clarify the basis of the hospital for its preference of the powder formulation for this medicine.*	This drug was considered based on the previous requests of the end-users, but we may consider to bid against Oxaliptin 5mg/ml concentrate solution, 10ml vial (IV Infusion) since the powder formulation is not available in the market now.

TERMS AND CONDITIONS:

Item No.	Query	Remarks / Response
2	The brand offered must be at least five (5) years commercially available in the market from date of opening of bids. Proof of this shall be the initial Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA).	The agency's requirement for the brand offered must be at least five (5) years commercially available in the market and the submission of Certificate of Acceptance from at least three (3) major hospitals shall remain to ensure that the offered drugs and medicines are already being used in major hospitals and not subject for any product recall or product complaint. A 5-year existence of a drug in the market will minimize risks and prioritized patient safety. This ensures that patients are not give drugs that have not undergone sufficient testing to establish safety and efficacy. Additional submission during the conduct of post-qualification may be imposed, if necessary,
6.1	Validation of the submitted Certificate of Acceptance from at least three (3) major hospitals	

Item No.	Query	Remarks / Response
		specifically on the submission of a published international or local clinical trial/study on the drug showing that is safe and effective for its intended use.
3.1	Memorandum of Agreement (MOA) and Certificate of exclusive / authorized distributorship between the manufacturer and distributor.	The title / heading of the required "MOA" may vary depending on the agreement executed by the manufacturer and exclusive / authorized distributor. However, the purpose of having the authority to submit tender for the product on behalf of the principal and that all commitments made by them shall be honored by the principal in case of termination of distribution agreement. Compliance with the submission of the Memorandum of Agreement and Certificate of exclusive / authorized distributorship between the manufacturer and distributor is required.
3.2	Valid Certificate of Product Registration (CPR) issued by the Food and Drug Administration (FDA). The name of the respective distributor should appear on the submitted CPR of the drug. Note: CPRs that will expire within three (3) months from the date of opening of bids should present the Official Receipt of renewal of application with the Document Tracking log for the CPR from the FDA.	Compliance of the company is required to submit proof of payment and filing. As stated in the FDA Circular No. 2011-004, the FDA considers the renewal of CPRs as valid and existing provided it is filed within the 120-day period (4 months) from its date of expiry. The hospital is still lenient in its requirement of three (3) months.
	On the request for certification for bidding purposes for the itemized list they intend to participate in the bidding. ➢ Certificate of Product Evaluation and Approval; ➢ Certificate of No Reported Serious Adverse Drug Reaction (ADR); ➢ Certificate of No Reported Problem or Issue raised by PGH Pharmacy from end-users	The prospective bidder is expected to comply with the requirements of the agency as stated in the bidding documents.

This shall form an integral part of the Bid Documents.

For the information and guidance of all concerned.

~Original Signed~
Dean CHARLOTTE M. CHIONG, MD, PhD
Chairperson, Bids and Awards Committee 1

Received by the Bidder:

_____
Signature over Printed Name

_____
Name of Company

_____
Date